Jason Napodano
Jason Napodano
Stop FollowingJason Napodano
View as an RSS Feed
View Jason Napodano's Articles BY TICKER:
-
LabStyle Innovations - Glucose Monitoring For The Mobile Age
-
A Look At Neurocrine's VMAT-2 Inhibitor As Phase IIb Data Nears
-
Review Of Depomed's First Quarter 2013 Results
-
Cipher Pharma Continues To Deliver
-
Why I Think InVivo Is Under-Valued
-
Amarantus' LymPro Could Be A Game-Changer For Alzheimer's Diagnosis
-
FDA Agrees To Expedited Path To NDA For Pimavanserin
-
Omni Bio Pharmaceutical's Better Solution For Treating An Orphan Disease, And More
-
Aastrom's Shocking News And Future Potential
-
Checking In On Organovo
-
What You Need To Know About Aastrom Bio
-
Tonix Readies For Pivotal Fibromyalgia Program
-
Valuing Amarantus - Where Financial Reality Meets Scientific Hope
- A Deal For Pozen's PA Could Send Shares Soaring
-
OxySure To Piggyback On AED Boom
-
Scientific Literature Suggests Amarantus' MANF Has Big Potential
-
OxySure Systems' Emergency Oxygen Device Ready For Takeoff
-
Transformation Underway At Cipher
-
Tonix: A Small Biotech With The Potentially Huge Key To The Fibromyalgia Puzzle
-
A Bare Bones Valuation On Zalicus: Over 40% Upside Potential
-
Looking At DepoMed's Serada For Hot Flashes
-
Neurocrine's VMAT-2 Enters Phase IIb
-
Reckitt's Decision Opens The Door For Titan Pharma And BioDelivery Sciences
-
Buy Pozen Ahead Of Key Medical Meetings
-
Titan Enters Exclusive Talks To Partner Probuphine
-
Time To Buy DARA Bio
-
Buy Durect As Visibility On Remoxy Improves
- What Lilly's Failure Means For Addex
-
Partnership For Addex Could Send Shares Higher
-
An In-Depth Look At Organovo
-
GAIN Act Should Benefit Antibiotic Makers
- CMS Coverage Big Positive For Cytomedix
